[ad_1]
Original Title: The Good News Continues for Vaccines, These Cold Chain Transport Companies Deserve Attention
On Tuesday, as the good news about vaccines spread one after another, the stock of the vaccine cold chain concept performed well. At the closure,Aoyang HealthDaily limit,Ice wheel environmentPink 7%,Hot and cold iceberg、Intel Group、AucmaWait for individual stocks to rise.
Following the positive news of the Pfizer and BioNTech vaccines last week, the American pharmaceutical company Moderna also announced yesterday that according to preliminary testing data, the effectiveness of its new phase III vaccine against coronary pneumonia was greater than 94%. .
According to foreign media reports, in an attempt to solve the challenge of extremely low-temperature storage in the vaccine distribution process, on the 16th local time, the US pharmaceutical company Pfizer launched a new corona vaccine pilot program. in four states of the United States. According to the report, Pfizer hopes to conduct large-scale, late-stage trials before the third week of November, in order to obtain sufficient data to demonstrate the safety of the vaccine, and then ask the United States for emergency use of the new corona vaccine.
The Bohai Securities Research Report noted that Pfizer and others have published positive results for the vaccine, and the market has initially removed doubts about the successful development of the vaccine. The clinical results of multiple vaccines at home and abroad are worthy of note. Attention. Some investors were skeptical about the success of the vaccine development. Although the protection rate will change as the trial progresses, this key milestone shows that the vaccine can prevent the new coronavirus. The risks of vaccine research and development have initially landed. It is recommended to pay attention to the main national vaccine companies and cold chain transportation companies with fast speeds of research and development, such asZhifei、Kangtai BiowithWatson Bio。
The Tou Leopard Research Institute’s research report noted that the cold chain pharmaceutical industry’s barriers to entry are high and the number of participants is small. In the future, the number of market participants in the cold chain pharmaceutical industry will continue to increase and competition within the industry will also intensify. In the past two years, many companies have seen unlimited business opportunities and market potential in the pharmaceutical cold chain industry and have entered the field of pharmaceutical cold chain. Not only companies whose core business is the pharmaceutical cold chain enter the market, but also third-party logistics companies that participate in it.
Massive information, accurate interpretation, all in the Sina Finance APP
Editor in charge: Zhang Mei
